CVM

Cel Sci (CVM)

Cel Sci Corporation New

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:AMEX:CVM

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2025/01/14	23 : 00	Business Wire	CEL-SCI Reports Fiscal 2024 Results: Set to Commence Confirmatory Study That Could Bring New Standard of Care to Head & Neck Cancer	AMEX:CVM	Cel Sci Corporation New
2025/01/14	06 : 16	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	AMEX:CVM	Cel Sci Corporation New
2025/01/04	07 : 25	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	AMEX:CVM	Cel Sci Corporation New
2025/01/03	04 : 25	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	AMEX:CVM	Cel Sci Corporation New
2025/01/03	04 : 18	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	AMEX:CVM	Cel Sci Corporation New
2025/01/03	04 : 12	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	AMEX:CVM	Cel Sci Corporation New
2025/01/01	06 : 15	Edgar (US Regulatory)	Form 8-K - Current report	AMEX:CVM	Cel Sci Corporation New
2025/01/01	06 : 05	Business Wire	CEL-SCI Announces Closing of $5 Million Offering	AMEX:CVM	Cel Sci Corporation New
2024/12/31	07 : 05	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	AMEX:CVM	Cel Sci Corporation New
2024/12/31	06 : 16	Edgar (US Regulatory)	Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405	AMEX:CVM	Cel Sci Corporation New
2024/12/30	10 : 41	Business Wire	CEL-SCI Announces Pricing of $5 Million Public Offering	AMEX:CVM	Cel Sci Corporation New
2024/12/28	07 : 05	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	AMEX:CVM	Cel Sci Corporation New
2024/12/28	07 : 05	Business Wire	CEL-SCI Announces Proposed Public Offering of Common Stock	AMEX:CVM	Cel Sci Corporation New
2024/12/12	23 : 15	Business Wire	CEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer Study	AMEX:CVM	Cel Sci Corporation New
2024/11/16	06 : 30	Edgar (US Regulatory)	Form 8-K - Current report	AMEX:CVM	Cel Sci Corporation New
2024/11/13	22 : 30	Edgar (US Regulatory)	Form 8-K - Current report	AMEX:CVM	Cel Sci Corporation New
2024/11/08	14 : 15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	AMEX:CVM	Cel Sci Corporation New
2024/11/07	22 : 15	Business Wire	U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025	AMEX:CVM	Cel Sci Corporation New
2024/10/31	06 : 21	Edgar (US Regulatory)	Form S-3/A - Registration statement under Securities Act of 1933: [Amend]	AMEX:CVM	Cel Sci Corporation New
2024/10/26	06 : 17	Edgar (US Regulatory)	Form S-3 - Registration statement under Securities Act of 1933	AMEX:CVM	Cel Sci Corporation New
2024/10/22	22 : 15	Business Wire	FDA’s Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI’s Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients	AMEX:CVM	Cel Sci Corporation New
2024/10/12	06 : 00	Edgar (US Regulatory)	Form POS AM - Post-Effective amendments for registration statement	AMEX:CVM	Cel Sci Corporation New
2024/10/11	05 : 05	Edgar (US Regulatory)	Form AW - Amendment Withdrawal Request	AMEX:CVM	Cel Sci Corporation New
2024/10/09	06 : 13	Edgar (US Regulatory)	Form S-3/A - Registration statement under Securities Act of 1933: [Amend]	AMEX:CVM	Cel Sci Corporation New
2024/10/01	22 : 13	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	AMEX:CVM	Cel Sci Corporation New
2024/10/01	22 : 05	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	AMEX:CVM	Cel Sci Corporation New
2024/10/01	21 : 58	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	AMEX:CVM	Cel Sci Corporation New
2024/10/01	19 : 00	Business Wire	CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer	AMEX:CVM	Cel Sci Corporation New
2024/09/16	20 : 30	Business Wire	CEL-SCI’s Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation	AMEX:CVM	Cel Sci Corporation New
2024/09/10	22 : 32	Business Wire	CEL-SCI to Present New Data for Multikine® Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 Congress	AMEX:CVM	Cel Sci Corporation New